Brain and behavior

Dexmedetomidine's effects on behavior in rats with chemically induced Alzheimer's disease

Updated

Abstract

Dexmedetomidine at 25 µg/kg significantly reverses cognitive deficits in STZ-treated rats.

  • Streptozotocin treatment in rats led to significant reductions in spontaneous alternation behavior in the Y-maze.
  • Dexmedetomidine improved performance in the Y-maze, reversing the cognitive deficits caused by STZ.
  • In the Morris water maze, STZ-treated rats showed longer escape latencies and increased path lengths compared to control animals.
  • Dexmedetomidine treatment resulted in significantly improved spatial learning and memory retention in STZ-treated rats.
  • No significant changes were found in locomotor activity or anxiety-related behaviors in the open-field test or elevated plus maze.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free